# A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years

Source: https://onco.cc/trials/nct05262010/  
OnCo record `nct05262010` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) in advanced solid tumours, run by National Vaccine and Serum Institute, China, now recruiting.

## Summary

A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years is a phase 3 interventional study registered as NCT05262010 by National Vaccine and Serum Institute, China, with 13500 participants planned, started 2022-06-04 and due to reach its primary completion in 2028-06. Interventions recorded: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha) and placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05262010
- Phase: 3
- Setting: A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
- Sponsor: National Vaccine and Serum Institute, China
- Enrolled: 13500

## Sources

- ClinicalTrials.gov NCT05262010: https://clinicaltrials.gov/study/NCT05262010

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct05262010.json